#Cancer diagnostics

[wikipediapictures]

Proteomics

“TECAN Genesis 2000 robot preparing Ciphergen SELDI-TOF protein chips for proteomic pattern analysis. Highly accurate cancer prognosis can be accomplished by identifying protein patterns of specific cancers using this device.” - via Wikimedia Commons

[andrewjhonson1234]

A recent review published in Cancers highlights the significant role of progranulin in cancer development. The growth factor has been found to promote tumor growth by enhancing cancer cell proliferation, migration, and resistance to chemotherapy. It also influences the tumor microenvironment and immune surveillance. Despite these findings, the molecular mechanisms behind progranulin’s oncogenic role are not yet fully understood. Researchers from the Sbarro Health Research Organization and Temple University suggest that further exploration of progranulin could lead to novel therapeutic strategies, including its potential as a diagnostic and prognostic marker for cancer.

[dssima]

Enhancing FISH Diagnostics with DSS Image Tech Instruments

Fluorescence In Situ Hybridization (FISH) is a pivotal technique in molecular diagnostics, enabling researchers and clinicians to identify genetic abnormalities with remarkable accuracy. DSS Image Tech, a leader in advanced diagnostic solutions, offers state-of-the-art instruments and reagents for FISH diagnostics, setting new standards in precision and efficiency.

What is FISH and Why is It Important?

FISH is a molecular cytogenetic technique used to detect and localize the presence or absence of specific DNA sequences on chromosomes. It plays a crucial role in:

Cancer Diagnostics: Identifying genetic markers linked to cancer progression.

Genetic Disorders: Detecting chromosomal abnormalities in prenatal and postnatal diagnostics.

Research Applications: Assisting in studies of gene mapping and structural variations.

DSS Image Tech’s Innovative FISH Instruments

DSS Image Tech offers cutting-edge tools designed to enhance the precision of FISH diagnostics. Key features include:

High Sensitivity and Accuracy: DSS instruments ensure precise hybridization, minimizing errors.

Automated Workflow: Simplified processes increase throughput and reduce manual intervention.

User-Friendly Interface: Designed for ease of use, making complex diagnostics accessible.

These instruments cater to laboratories of all scales, ensuring that professionals have reliable tools to deliver accurate results.

FISH Reagents by DSS Image Tech

In addition to instruments, DSS provides a comprehensive range of FISH reagents, ensuring compatibility and consistent performance. Their reagents:

Offer superior signal-to-noise ratios.

Enable reproducible results across diverse sample types.

Meet rigorous quality standards for clinical and research applications.

Advantages of DSS FISH Solutions

Time-Efficient Diagnostics: Streamlined processes allow for faster turnaround times.

Cost-Effectiveness: Optimized resource utilization reduces operational costs.

Wide Applications: From oncology to genetic counseling, DSS solutions support various diagnostic needs.

Applications in Clinical and Research Settings

DSS FISH diagnostics empower professionals in:

Oncology: Identifying HER2 amplifications or ALK rearrangements in tumors.

Prenatal Screening: Detecting aneuploidies like trisomy 21.

Genetic Counseling: Providing actionable insights for inherited conditions.

Why Choose DSS Image Tech?

With a commitment to innovation, DSS Image Tech combines expertise and technology to revolutionize diagnostics. Their focus on quality, precision, and customer support makes them a trusted partner in molecular diagnostics.

Conclusion

Fluorescence In Situ Hybridization (FISH) continues to transform diagnostics, and DSS Image Tech remains at the forefront of this evolution. By offering advanced instruments and high-quality reagents, DSS empowers laboratories to achieve precision in genetic analysis.

[pathologylab]

Join Us for an Insightful #Webinar!

We are excited to invite you to our upcoming webinar, "Explore the Future of Cancer Diagnostics with #Genes2Me Comprehensive Genomic Profiling—PanCan."

📅 : October 30, 2024 (Wednesday)

⏰ : 4:30 PM IST

🌍 : Register now and be part of this webinar : https://docs.google.com/forms/d/1tqdsIYlWVhExQQY4huCHT17ivAkOqY5EMwxAcmbUrRM/edit

#CancerDiagnostics #GenomicProfiling #diagnostics #testing #awareness #G2M #PanCan #PersonalizedMedicine #FutureOfHealthcare

[creativeera]

Cancer Biomarkers Market Poised to Exhibit a CAGR of 7.3% by 2031

Cancer biomarkers are substances whose presence is indicative of some biological condition, processes, or pathology. They can be used for cancer diagnosis or checking effectiveness of treatment. Being non-invasive procedures, demand for cancer biomarkers is growing rapidly. They aid in early detection of cancer during screening programs and reduce cost of cancer treatment. Global cancer biomarkers market is estimated to be valued at USD 25.60 Bn in 2024 and is expected to reach USD 59.01 Bn by 2031, exhibiting a compound annual growth rate (CAGR) of 12.7% from 2024 to 2031.

Key Takeaways Key players operating in the Cancer Biomarkers market are Schlumberger Limited, Rockwell Automation Inc., SIS-TECH Solutions LP, Emerson Electric Company, HIMA Paul Hildebrandt GmbH, Honeywell International Inc., Siemens AG, Yokogawa Electric Corporation, Schneider Electric SE, and ABB Ltd. They are investing heavily in biomarker detection methods and panels targeting unmet clinical needs. Rising incidence of cancer across the world is driving for Cancer Biomarkers Market Demand. Biomarkers help in cancer screening and detecting disease at early stages. This improves treatment outcomes and survival rates significantly. Initiatives by governments and cancer councils to spread cancer awareness are also boosting the market. Global expansion strategies adopted by leading players are expected to support market growth during the forecast period. They are expanding their footprint in emerging markets of Asia Pacific, Latin America, and Middle East & Africa to tap the high growth opportunities. This will increase access to advanced cancer diagnostic solutions. Market Key Trends The use of artificial intelligence and machine learning algorithms to discover novel biomarkers from large datasets is a key trend in the market. It helps accelerate the process of biomarker identification. Genomic and proteomic biomarkers are also gaining traction for their role in cancer detection as well as tracking cancer progression and drug response. Development of personalized diagnostics based on multi-omics approaches and liquid biopsy tests are some other trends expected to shape the market.

Porter’s Analysis Threat of new entrants: The cancer biomarkers market requires huge capital investments in R&D for developing novel biomarkers and testing kits which makes the entry difficult for new players. Bargaining power of buyers: Buyers have moderate bargaining power in this market as there are many players offering similar cancer biomarker testing services. Bargaining power of suppliers: Suppliers have low bargaining power due to availability of alternative raw material suppliers in the market. Threat of new substitutes: Substitutes have low threat as there are limited substitutes available for cancer biomarker tests. Competitive rivalry: The market is highly competitive due to presence of many global as well as regional players. Geographical Regions North America region accounts for the largest share of the cancer biomarkers market in terms of value due to presence of major players, rising healthcare expenditure and increasing prevalence of cancer in the region. Asia Pacific is expected to grow at the fastest CAGR during the forecast period owing to increasing awareness regarding cancer, improving healthcare infrastructure and rising access to diagnostic services in emerging economies of China and India in this region.

Get more insights on Cancer Biomarkers Market

About Author:

Money Singh is a seasoned content writer with over four years of experience in the market research sector. Her expertise spans various industries, including food and beverages, biotechnology, chemical and materials, defense and aerospace, consumer goods, etc. (https://www.linkedin.com/in/money-singh-590844163)

[pathologylab]

#Lungcancer impacts not just individuals but also families, communities, and the #world. Together, we can make a significant impact in the fight against lung #cancer.

On this #WorldLungCancerDay, let us remember that awareness is the first step towards prevention and healing. #G2M is delighted to support this cause and be a part of this awareness drive. G2M introduces the ctDNA #LungPanel, a robust #NGS Liquid biopsy solution. Our #panel offers comprehensive coverage of the entire coding #sequence and critical hotspots, ensuring thorough detection of SNVs, InDels, and CNVs with unparalleled accuracy. With high-depth #sequencing with recommended coverage of 7000–8000X and an optimized target size of 110 kb specifically designed for lung cancer, our panel sets a new standard in precision #diagnostics.

The ctDNA Lung Panel is highly optimized for clinical testing, providing exceptional accuracy. It includes high-quality NGS data analysis #software that enables efficient duplication removal and minimizes sequencing noise, ensuring reliable results.

Join us in raising #awareness and advancing diagnostic capabilities.

#LungCancerAwareness #CancerDiagnostics #MolecularDiagnostics #HealthcareInnovation #genes2me #dna #liquidbiopsy #solution #testing #clinical #analysis #worldlungcancerday2024 #lungcancerday2024 #lungpanel #cancerday #cancerday2024

[aishavass]

The magnificent growth is attributed to rising prevalence of cancer and increasing public health awareness. In the present scenario North America is...

[poojascmi]

Global Cancer Diagnostics Market Is Estimated To Witness High Growth Owing To Increasing Demand for Early Cancer Detection

The global Cancer Diagnostics market is estimated to be valued at US$ 59.1 billion in 2023 and is expected to exhibit a CAGR of 9.6% over the forecast period 2023-2030, as highlighted in a new report published by Coherent Market Insights. A) Market Overview: The Cancer Diagnostics market includes various diagnostic tools and techniques used for the early detection, diagnosis, and management of cancer. These diagnostics play a crucial role in determining the type, stage, and treatment plan for cancer patients. The market offers a wide range of products such as antibodies, biomarkers, imaging modalities, and molecular tests. The increasing prevalence of cancer and the need for early detection are driving the demand for cancer diagnostics. These diagnostics provide numerous advantages, including precise diagnosis, targeted therapies, and personalized treatment plans, ultimately improving patient outcomes. B) Market key trends: One key trend shaping the Cancer Diagnostics market is the growing emphasis on liquid biopsies. Liquid biopsies refer to the non-invasive testing of tumor biomarkers from bodily fluids such as blood or urine. They offer several advantages over traditional tissue biopsies, including the ability to monitor cancer progression and treatment response in real-time. Liquid biopsies also enable early detection of cancer recurrence and minimal invasiveness for patients. For example, companies like Natera, Inc. have developed liquid biopsy tests, such as Signatera, which can detect minimal residual disease in colorectal cancer patients with high sensitivity. C) PEST Analysis: - Political: Governments worldwide are focusing on implementing cancer control programs and increasing funding for cancer research. This political support is driving the growth of the Cancer Diagnostics market. For instance, the National Cancer Moonshot Initiative in the United States aims to accelerate progress in cancer prevention, diagnosis, and treatment. - Economic: The rising healthcare expenditure and growing disposable income of individuals are fueling the demand for advanced cancer diagnostics. Additionally, the cost-effectiveness of these diagnostics in terms of improved patient outcomes and reduced treatment costs is contributing to market growth. - Social: The increasing awareness about the importance of early cancer detection and the proactive approach towards healthcare are positively influencing the market. Moreover, factors such as lifestyle changes, tobacco consumption, and unhealthy diets are contributing to the rising incidence of cancer. - Technological: Technological advancements in diagnostic techniques, such as next-generation sequencing, liquid biopsies, and companion diagnostics, are driving market growth. These advancements enable earlier detection, better accuracy, and personalized treatment approaches. D) Key Takeaways: Paragraph 1: The Global Cancer Diagnostics Market Size is expected to witness high growth, exhibiting a CAGR of 9.6% over the forecast period. This growth is primarily attributed to increasing demand for early cancer detection. Early diagnosis plays a critical role in improving patient outcomes and reducing the overall burden of cancer. Paragraph 2: Regionally, North America dominates the Cancer Diagnostics market due to factors such as a high prevalence of cancer, well-established healthcare infrastructure, and government initiatives towards cancer control. However, Asia Pacific is expected to witness the fastest growth during the forecast period. The increasing healthcare expenditure, growing awareness about cancer, and improving access to healthcare facilities are driving market growth in this region.

[d-adpool]

Dude don't you know someone who said to sniff for skin cancer?

first of all my friend said he could TASTE cancer which is a different thing entirely but 1 skin cancer is seldom found in a place you can lick and 2 i think he's full of shit anyway

[perplexed-penguin]

After today I think I deserve a 1 hour screaming session in the mountains.

[rhysintherain]

For a show about diagnostic medicine, House does shockingly little actual diagnosis.

"Start him on antibiotics." Have you seen a bacteria? No? That's because apparently nobody on your team knows how to grow a culture or run a gram stain.

"It's probably cancer, start him on radiation." Without finding the cancer?? Without knowing what it is so you can decide on a treatment plan??

Very funny that actual diagnosis is too boring for House, so he just throws treatments at people until it almost kills them and demonstrates what the problem isn't.

[innonurse]

Mark your calendar for these health tech conferences in 2024-2025

- By InnoNurse Staff -

Interested in health technology-related events for fall 2024 and 2025? Fierce Healthcare has compiled a list of key conferences, both virtual and in-person, scheduled for the upcoming seasons.

Read more at Fierce Healthcare

///

Other recent news and insights

Lapsi transforms the stethoscope into a health tracking data platform (TechCrunch)

UK: The Department of Health and Social Care set to review clinical risk standards for digital health technologies (Digital Health)

AI-based cancer test determines if chemotherapy is needed (The Financial Express)

New tool enhances microscopic imaging by eliminating motion artifacts (UC Berkeley/Tech Xplore)

Researchers integrate a fast optical coherence tomography system into neurosurgical microscopes (Optica)

AI model achieves clinical-expert-level accuracy in complex medical scans (UCLA/Medical Xpress)

Bioinformatics reveals the hidden prevalence of repeat expansion disorders (Queen Mary University of London/Medical Xpress)

Ultrasound detects 96% of ovarian cancers in postmenopausal women (University of Birmingham)

AI ‘liquid biopsies’ using cell-free DNA and protein biomarkers could improve early ovarian cancer detection (Johns Hopkins Technology Ventures)

Mammograms show potential for detecting heart disease (UC San Diego/Medical Xpress)

IMRT and proton therapy provide similar quality of life and tumor control for prostate cancer patients (American Society for Radiation Oncology/Medical Xpress)

Machine learning enhances MRI video quality (Graz University of Technology/Medical Xpress)

Robotic surgery for colorectal cancer reduces pain and accelerates recovery (Beth Israel Deaconess Medical Center)

Global human brain mapping project releases its first data set (Allen Institute)

AI could speed up PCR tests, aiding faster DNA diagnostics and forensics (Flinders University/Medical Xpress)

AI-powered apps may detect depression through eye snapshots (Stevens Institute of Technology/Medical Xpress)

[romantichopelessly]

i've never really had a therapist, but i've seen posts and heard people talking about texting their therapist with issues and. my doctor is so lucky that i do not have a direct line to him. i would be sending him articles at 10am on a thursday with the caption "i think i have lymphoma, wby?"

[aishavass]

The magnificent growth is attributed to rising prevalence of cancer and increasing public health awareness. In the present scenario North America is...